Childhood acute lymphoblastic leukemia in the Netherlands - Randomized studies and nationwide treatment results from 1972 to 1995

AV Does-Van den Berg, AJP Veerman, ER Van Wering, JA De Vries, FC De Waal, GE Van Zanen, JF Van Weerden, WA Kamps

    Research output: Contribution to journalArticleAcademicpeer-review

    11 Citations (Scopus)

    Abstract

    The Dutch Childhood Leukemia Study Group (DCLSG) has implemented eight protocols for the treatment of childhood acute lymphoblastic leukemia (ALL) (ALL I to VIII) during the period from 1972 to 1995. They were based on St. Jude's Total Therapy (ALL II to VI) and the risk-adapted intensive therapy (ALL VII and VIII) developed by the BFM Group, respectively, and included seven randomized studies. In study ALT, I (N = 43, 1972 to 1973), no effect was observed after the addition of daunorubicin to vincristine/prednisone pulses during maintenance treatment. In study ALL II (N = 143, 1973 to 1975) the addition of cyclophosphamide to maintenance treatment with 6-mercaptopurine/methotrexate increased toxicity and mortality without increasing the event-free survival rate. In study ALL III (N = 148; 1975 to 1979) for non-high-risk patients (defined as initial leukocyte count

    Original languageEnglish
    Pages (from-to)125-139
    Number of pages15
    JournalInternational journal of pediatric hematology/oncology
    Volume5
    Issue number2-4
    Publication statusPublished - 1998

    Keywords

    • acute lymphoblastic leukemia
    • childhood
    • event-free survival
    • randomized trials
    • clinical studies
    • ACUTE LYMPHOCYTIC-LEUKEMIA
    • CENTRAL NERVOUS-SYSTEM
    • LONG-TERM SURVIVORS
    • CHILDREN
    • CLASSIFICATION
    • THERAPY
    • RISK

    Cite this